KBI BioPharma Capabilities Update July 2026: Large Molecule

Achieving high, consistent expression for complex biologics frequently stalls early development due to laborious vector design and time-consuming clone screening. By combining targeted transposon technology with stable bulk pool generation, biopharma developers can significantly compress cell line development timelines. Utilizing optimized host cell platforms enables higher transgene integration and copy numbers with minimal manual intervention. Concurrently, rapid bulk pool workflows produce representative protein material earlier in the process, eliminating the reliance on transient transfections and allowing for more accurate early candidate screening. This integrated strategy de-risks lead selection, accelerates early material generation, and optimizes the path to clinical trials without sacrificing expression quality or stability.

Explore how advanced cell line development strategies can streamline your early-stage pipeline.